

Provided for non-commercial research and education use.  
Not for reproduction, distribution or commercial use.

	<h1>JACC</h1> <p>JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY</p>	MARCH 24, 2020 VOLUME 75 NUMBER 11
<b>ORIGINAL INVESTIGATIONS</b>	<b>THE PRESENT AND FUTURE</b>	
1249 Lipid Accumulation in Hearts Transplanted From Nondiabetic Donors to Diabetic Recipients R. Marfella, C. Napoli, et al. ■ <b>EDITORIAL</b> Frequent, Forgotten, and Often Fatal C.M. Alexander	1324 <b>JACC STATE-OF-THE-ART REVIEW</b> Inflammation in Heart Failure S.P. Murphy, J.L. Januzzi, Jr., et al.	
1266 Transcatheter Correction of Superior Sinus Venous Atrial Septal Defects as an Alternative to Surgical Treatment J.H. Hansen, E. Rosenthal, et al. ■ <b>EDITORIAL</b> <i>Usus Est Magister Optimus</i> L. Benson, M. Osten, et al.	1341 <b>JACC REVIEW TOPIC OF THE WEEK</b> Select Drug-Drug Interactions With Direct Oral Anticoagulants B.S. Wiggins, T.J. Gluckman, et al.	
1281 Multiple Plasma Biomarkers for Risk Stratification in Patients With Heart Failure and Preserved Ejection Fraction J.A. Chirinos, T.P. Cappola, et al. ■ <b>EDITORIAL</b> A Biomarker Approach D.W. Kitzman, G.M. Felker, et al.	<b>LEADERSHIP PAGE</b>	
1299 Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease S.D. Pokorney, J.P. Piccini, Sr., et al. ■ <b>EDITORIAL</b> When Oral Anticoagulation Becomes Difficult J.B. Olesen, A.N. Bonde	1351 The State of the States 2019: ACC Chapter Highlights A. Khandelwal, A. Betz, et al.	
1311 Contrast-Associated Acute Kidney Injury and Serious Adverse Outcomes Following Angiography S.D. Webb, M. Gallagher, et al. ■ <b>EDITORIAL</b> Innocent, Guilty, and AHI H.L. Dauerman, R.J. Solomon	<b>FELLOWS-IN-TRAINING &amp; EARLY CAREER SECTION</b>	
	1355 Cardio-Obstetrics: Developing a Niche in Maternal Cardiovascular Health G. Sharma, A. Grodzinsky, et al. ■ <b>RESPONSE</b> Cardio-Obstetrics: Time to Assess M.N. Walsh	
	1360 <b>LETTERS</b>	
	 Audio summaries from Dr. Valentin Fuster, JACC Editor-in-Chief.	
<a href="http://www.onlinejacc.org">www.onlinejacc.org</a>	<b>ELSEVIER</b> ISSN 0735-1097	

This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the author's institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/authorsrights>

Please note: Drs. Dagres, Bollmann, and Hindricks have received research grants from Abbott and Boston Scientific to their institution without personal financial benefits. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

## REFERENCE

1. Guo Y, Wang H, Zhang H, et al. Mobile photoplethysmographic technology to detect atrial fibrillation. *J Am Coll Cardiol* 2019;74:2365-75.

# Atrial Fibrillation Episodes Detected Using Photoplethysmography



## Do We Know Which Are True?

We read with great interest the recent publication on the Huawei Heart study by Guo et al. (1). The authors reported impressive work that significantly advances current knowledge on the feasibility of atrial fibrillation (AF) screening in daily life with already marketed wearable technologies measuring photoplethysmography (PPG). However, we are concerned about the limitations in the methodology that was used to determine the accuracy of detecting AF episodes.

Several authors have previously criticized the use of PPG technologies for AF screening because of the risk related to poor accuracy, which may have a negative impact on the patient and on the health care system. In the Huawei Heart study, the authors report the positive predictive value (PPV) of PPG signals to be 91.6%, which is very promising considering concerns about false positive detections. However, this result should be interpreted with caution.

The greatest problem is that Guo et al. (1) have derived detection accuracy of AF episodes based on an assumption that the suspected AF episodes were either all true or all false based on the final diagnosis at follow-up. This assumption may result in overestimation or underestimation of PPV, which, in turn, can lead to having the wrong impact on the acceptance of the technology. We previously reported in a smaller study that high PPVs up to 100% can be obtained in ambulatory settings (2,3), but in terms of study design, the fairest comparison should be made with the Apple Heart Study (4). There, preliminary results report a PPV of 71%, compared to which 91.6% is a significant improvement. Because every AF event counts, electrocardiographic reference should be available when adjudicating AF episodes as being true. This can make a difference in the fair evaluation

of the PPG technologies for improving care and management for AF patients.

\*Linda M. Eerikäinen, MSc

Alberto G. Bonomi, PhD

Lukas R.C. Dekker, MD, PhD

Ronald M. Aarts, PhD

\*Department of Electrical Engineering  
Eindhoven University of Technology

P.O. Box 513

5600 MB Eindhoven

the Netherlands

E-mail: [L.M.Eerikainen@tue.nl](mailto:L.M.Eerikainen@tue.nl)

<https://doi.org/10.1016/j.jacc.2019.10.064>

© 2020 by the American College of Cardiology Foundation. Published by Elsevier.

Please note: Ms. Eerikäinen is a guest researcher at Philips Research but has no financial relationship with Philips Research to disclose. Dr. Bonomi is employed by Philips Research. Dr. Dekker has received consultancy fees from Philips. Dr. Aarts is a former employee of Philips Research.

## REFERENCES

1. Guo Y, Wang H, Zhang H, et al. Mobile photoplethysmographic technology to detect atrial fibrillation. *J Am Coll Cardiol* 2019;74:2365-75.

2. Bonomi AG, Schipper F, Eerikäinen LM, et al. Atrial fibrillation detection using a novel cardiac ambulatory monitor based on photo-plethysmography at the wrist. *J Am Heart Assoc* 2018;7. 15:e009351.

3. Eerikäinen LM, Bonomi AG, Schipper F, et al. Comparison between electrocardiogram- and photoplethysmogram-derived features for atrial fibrillation detection in free-living conditions. *Physiol Meas* 2018;39:084001.

4. Apple Heart Study Demonstrates Ability of Wearable Technology to Detect Atrial Fibrillation. Stanford Medicine News Center. Available at: <https://med.stanford.edu/news/all-news/2019/03/apple-heart-study-demonstrates-ability-of-wearable-technology.html>. Accessed October 4, 2019.

# The Efficacy and Feasibility of Atrial Fibrillation Screening Using Photoplethysmography-Based Smart Devices



I read with great interest the study by Guo et al. (1) that examined the efficacy of atrial fibrillation (AF) screening using smart devices with photoplethysmography technology. They noted the high positive predictive value of photoplethysmography signals. Patients with confirmed AF were then enrolled into an app-based integrated care program with the Mobile Atrial Fibrillation Application, and 80% of participants deemed to be at high risk were given oral anticoagulants.